{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:19:02Z","timestamp":1790212742171,"version":"4.1.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals SA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40121-024-00963-w","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T11:01:56Z","timestamp":1713956516000},"page":"1083-1104","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Systematic Literature Review on the Incidence of Herpes Zoster in Populations at Increased Risk of Disease in the EU\/EEA, Switzerland, and the UK"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1046-9702","authenticated-orcid":false,"given":"Alen","family":"Marijam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki","family":"Vroom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Bhavsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Posiuniene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Lecrenier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Vroling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"issue":"1","key":"963_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/jdv.13995","volume":"31","author":"RN Werner","year":"2017","unstructured":"Werner RN, Nikkels AF, Marinovi\u0107 B, et al. European consensus-based (S2k) guideline on the management of herpes zoster \u2013 guided by the European dermatology forum (EDF) in cooperation with the European academy of dermatology and venereology (EADV), part 1: diagnosis. J Eur Acad Dermatol Venereol. 2017;31(1):9\u201319. https:\/\/doi.org\/10.1111\/jdv.13995.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"963_CR2","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1093\/cid\/ciz1090","volume":"71","author":"SL McKay","year":"2020","unstructured":"McKay SL, Guo A, Pergam SA, Dooling K. Herpes zoster risk in immunocompromised adults in the United States: a systematic review. Clin Infect Dis. 2020;71(7):e125\u201334. https:\/\/doi.org\/10.1093\/cid\/ciz1090.","journal-title":"Clin Infect Dis"},{"issue":"12 Suppl 2","key":"963_CR3","doi-asserted-by":"publisher","first-page":"S429","DOI":"10.1093\/infdis\/jiab387","volume":"224","author":"R Harbecke","year":"2021","unstructured":"Harbecke R, Cohen JI, Oxman MN. Herpes zoster vaccines. J Infect Dis. 2021;224(12 Suppl 2):S429\u201342. https:\/\/doi.org\/10.1093\/infdis\/jiab387.","journal-title":"J Infect Dis"},{"issue":"3","key":"963_CR4","doi-asserted-by":"publisher","first-page":"2263979","DOI":"10.1080\/21645515.2023.2263979","volume":"19","author":"R Parikh","year":"2023","unstructured":"Parikh R, Singer D, Chmielewski-Yee E, Dessart C. Effectiveness and safety of recombinant zoster vaccine: a review of real-world evidence. Hum Vaccin Immunother. 2023;19(3):2263979. https:\/\/doi.org\/10.1080\/21645515.2023.2263979.","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"963_CR5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/21645515.2019.1657753","volume":"16","author":"A Volpi","year":"2020","unstructured":"Volpi A, Boccalini S, Dari S, et al. The potential public health impact of herpes zoster vaccination in the 65 years of age cohort in Italy. Hum Vaccin Immunother. 2020;16(2):327\u201334. https:\/\/doi.org\/10.1080\/21645515.2019.1657753.","journal-title":"Hum Vaccin Immunother"},{"key":"963_CR6","unstructured":"European Centre for Disease Prevention and Control (ECDC). Vaccine Scheduler. https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=51&SelectedCountryIdByDisease=-1. Accessed Oct 10 2022."},{"key":"963_CR7","unstructured":"CDC. Shingles overview. https:\/\/www.cdc.gov\/shingles\/about\/index.html. Accessed Sept 10 2022."},{"key":"963_CR8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/1471-2334-13-170","volume":"13","author":"S Pinchinat","year":"2013","unstructured":"Pinchinat S, Cebri\u00e1n-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013;13:170. https:\/\/doi.org\/10.1186\/1471-2334-13-170.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"963_CR9","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40121-021-00567-8","volume":"11","author":"D Curran","year":"2022","unstructured":"Curran D, Callegaro A, Fahrbach K, et al. Meta-regression of herpes zoster incidence worldwide. Infect Dis Ther. 2022;11(1):389\u2013403. https:\/\/doi.org\/10.1007\/s40121-021-00567-8.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"963_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12877-017-0420-9","volume":"17","author":"L Varghese","year":"2017","unstructured":"Varghese L, Standaert B, Olivieri A, Curran D. The temporal impact of aging on the burden of herpes zoster. BMC Geriatr. 2017;17(1):1\u20137.","journal-title":"BMC Geriatr"},{"issue":"2","key":"963_CR11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3390\/v14020192","volume":"14","author":"A Patil","year":"2022","unstructured":"Patil A, Goldust M, Wollina U. Herpes zoster: a review of clinical manifestations and management. Viruses. 2022;14(2):192. https:\/\/doi.org\/10.3390\/v14020192.","journal-title":"Viruses"},{"issue":"8","key":"963_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255877","volume":"16","author":"AE Bardach","year":"2021","unstructured":"Bardach AE, Palermo C, Alconada T, et al. Herpes zoster epidemiology in Latin America: a systematic review and meta-analysis. PLoS ONE. 2021;16(8): e0255877. https:\/\/doi.org\/10.1371\/journal.pone.0255877.","journal-title":"PLoS ONE"},{"issue":"1","key":"963_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/j.pain.0000000000000307","volume":"157","author":"HJ Forbes","year":"2016","unstructured":"Forbes HJ, Thomas SL, Smeeth L, et al. A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain. 2016;157(1):30\u201354. https:\/\/doi.org\/10.1097\/j.pain.0000000000000307.","journal-title":"Pain"},{"issue":"6","key":"963_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-004833","volume":"4","author":"K Kawai","year":"2014","unstructured":"Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6): e004833. https:\/\/doi.org\/10.1136\/bmjopen-2014-004833.","journal-title":"BMJ Open"},{"key":"963_CR15","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1186\/s12889-015-1753-y","volume":"15","author":"H Bricout","year":"2015","unstructured":"Bricout H, Haugh M, Olatunde O, Prieto RG. Herpes zoster-associated mortality in Europe: a systematic review. BMC Public Health. 2015;15:466. https:\/\/doi.org\/10.1186\/s12889-015-1753-y.","journal-title":"BMC Public Health"},{"issue":"6","key":"963_CR16","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1080\/21645515.2020.1847582","volume":"17","author":"D van Oorschot","year":"2021","unstructured":"van Oorschot D, Vroling H, Bunge E, Diaz-Decaro J, Curran D, Yawn B. A systematic literature review of herpes zoster incidence worldwide. Hum Vaccin Immunother. 2021;17(6):1714\u201332.","journal-title":"Hum Vaccin Immunother"},{"key":"963_CR17","unstructured":"Higgins JP, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions v6.3. https:\/\/training.cochrane.org\/handbook\/current. Accessed Apr 19 2023."},{"key":"963_CR18","unstructured":"Preferred reporting items for systematic reviews and meta-analyses (PRISMA). http:\/\/prisma-statement.org\/. Accessed Apr 19 2023."},{"key":"963_CR19","unstructured":"European Centre for Disease Prevention and Control (ECDC). https:\/\/ecdc.europa.eu\/en\/home. Accessed Oct 4 2022."},{"key":"963_CR20","unstructured":"European Commission (EC). https:\/\/ec.europa.eu\/commission\/index_en. Accessed Oct 4 2022."},{"key":"963_CR21","unstructured":"EuroSurveillance. https:\/\/www.eurosurveillance.org\/. Accessed Oct 4 2022."},{"key":"963_CR22","unstructured":"World Health Organization (WHO). https:\/\/www.who.int\/. Accessed Oct 4 2022."},{"key":"963_CR23","unstructured":"EuroStat. https:\/\/ec.europa.eu\/eurostat. Accessed Oct 4 2022."},{"key":"963_CR24","unstructured":"United Nations Statistics Division. https:\/\/unstats.un.org\/home\/. Accessed Oct 4 2022."},{"issue":"5","key":"963_CR25","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/bjh.16729","volume":"191","author":"F Barraco","year":"2020","unstructured":"Barraco F, Greil R, Herbrecht R, et al. Real-world non-interventional long-term post-authorisation safety study of ruxolitinib in myelofibrosis. Br J Haematol. 2020;191(5):764\u201374. https:\/\/doi.org\/10.1111\/bjh.16729.","journal-title":"Br J Haematol"},{"issue":"3","key":"963_CR26","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s13555-021-00535-7","volume":"11","author":"M Batram","year":"2021","unstructured":"Batram M, Witte J, Schwarz M, et al. Burden of herpes zoster in adult patients with underlying conditions: analysis of German claims data, 2007\u20132018. Dermatol Ther (Heidelb). 2021;11(3):1009\u201326. https:\/\/doi.org\/10.1007\/s13555-021-00535-7.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"963_CR27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12931-018-0742-y","volume":"19","author":"M Bloechliger","year":"2018","unstructured":"Bloechliger M, Reinau D, Spoendlin J, et al. Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis. Respir Res. 2018;19(1):75. https:\/\/doi.org\/10.1186\/s12931-018-0742-y.","journal-title":"Respir Res"},{"key":"963_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2019.100007","volume":"1","author":"K Bollaerts","year":"2019","unstructured":"Bollaerts K, Alexandridou M, Verstraeten T. Risk factors for modified vaccine effectiveness of the live attenuated zoster vaccine among the elderly in England. Vaccine X. 2019;1: 100007. https:\/\/doi.org\/10.1016\/j.jvacx.2019.100007.","journal-title":"Vaccine X"},{"issue":"6","key":"963_CR29","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.4161\/hv.28620","volume":"10","author":"MD Esteban-Vasallo","year":"2014","unstructured":"Esteban-Vasallo MD, Dom\u00ednguez-Berj\u00f3n MF, Gil-Prieto R, Astray-Mochales J, Gil de Miguel A. Sociodemographic characteristics and chronic medical conditions as risk factors for herpes zoster: a population-based study from primary care in Madrid (Spain). Hum Vaccin Immunother. 2014;10(6):1650\u201360. https:\/\/doi.org\/10.4161\/hv.28620.","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"963_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/tri.13076","volume":"31","author":"M Fern\u00e1ndez-Ruiz","year":"2018","unstructured":"Fern\u00e1ndez-Ruiz M, Orig\u00fcen J, Lora D, et al. Herpes zoster in kidney transplant recipients: protective effect of anti-cytomegalovirus prophylaxis and natural killer cell count: a single-center cohort study. Transpl Int. 2018;31(2):187\u201397. https:\/\/doi.org\/10.1111\/tri.13076.","journal-title":"Transpl Int"},{"issue":"2","key":"963_CR31","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1136\/annrheumdis-2011-201108","volume":"72","author":"JB Galloway","year":"2013","unstructured":"Galloway JB, Mercer LK, Moseley A, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for rheumatology biologics register. Ann Rheum Dis. 2013;72(2):229\u201334. https:\/\/doi.org\/10.1136\/annrheumdis-2011-201108.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"963_CR32","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1093\/cid\/ciu1161","volume":"60","author":"S Grabar","year":"2015","unstructured":"Grabar S, Tattevin P, Selinger-Leneman H, et al. Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort. Clin Infect Dis. 2015;60(8):1269\u201377. https:\/\/doi.org\/10.1093\/cid\/ciu1161.","journal-title":"Clin Infect Dis"},{"key":"963_CR33","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/1471-2334-13-372","volume":"13","author":"K Jansen","year":"2013","unstructured":"Jansen K, Haastert B, Michalik C, et al. Incidence and risk factors of herpes zoster among HIV-positive patients in the German competence network for HIV\/AIDS (KompNet): a cohort study analysis. BMC Infect Dis. 2013;13:372. https:\/\/doi.org\/10.1186\/1471-2334-13-372.","journal-title":"BMC Infect Dis"},{"key":"963_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.645718","volume":"12","author":"MML Kho","year":"2021","unstructured":"Kho MML, Roest S, Bov\u00e9e DM, et al. Herpes zoster in solid organ transplantation: incidence and risk factors. Front Immunol. 2021;12: 645718. https:\/\/doi.org\/10.3389\/fimmu.2021.645718.","journal-title":"Front Immunol"},{"issue":"11","key":"963_CR35","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1080\/21645515.2017.1368600","volume":"13","author":"C Mu\u00f1oz-Quiles","year":"2017","unstructured":"Mu\u00f1oz-Quiles C, L\u00f3pez-Lacort M, Ampudia-Blasco FJ, D\u00edez-Domingo J. Risk and impact of herpes zoster on patients with diabetes: a population-based study, 2009\u20132014. Hum Vaccin Immunother. 2017;13(11):2606\u201311. https:\/\/doi.org\/10.1080\/21645515.2017.1368600.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"963_CR36","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12879-018-3121-x","volume":"18","author":"C Mu\u00f1oz-Quiles","year":"2018","unstructured":"Mu\u00f1oz-Quiles C, L\u00f3pez-Lacort M, D\u00edez-Domingo J. Risk and impact of herpes zoster among COPD patients: a population-based study, 2009\u20132014. BMC Infect Dis. 2018;18(1):203. https:\/\/doi.org\/10.1186\/s12879-018-3121-x.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"963_CR37","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1186\/s12879-020-05648-6","volume":"20","author":"C Mu\u00f1oz-Quiles","year":"2020","unstructured":"Mu\u00f1oz-Quiles C, L\u00f3pez-Lacort M, D\u00edez-Domingo J, Orrico-S\u00e1nchez A. Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009\u20132014. BMC Infect Dis. 2020;20(1):905. https:\/\/doi.org\/10.1186\/s12879-020-05648-6.","journal-title":"BMC Infect Dis"},{"key":"963_CR38","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s12879-015-1038-1","volume":"15","author":"ID Pavlopoulou","year":"2015","unstructured":"Pavlopoulou ID, Poulopoulou S, Melexopoulou C, Papazaharia I, Zavos G, Boletis IN. Incidence and risk factors of herpes zoster among adult renal transplant recipients receiving universal antiviral prophylaxis. BMC Infect Dis. 2015;15:285. https:\/\/doi.org\/10.1186\/s12879-015-1038-1.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"963_CR39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1136\/annrheumdis-2021-220651","volume":"81","author":"I Redeker","year":"2021","unstructured":"Redeker I, Albrecht K, Kekow J, et al. Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register. Ann Rheum Dis. 2021;81(1):41\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220651.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"963_CR40","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/rheumatology\/key023","volume":"57","author":"AI Rutherford","year":"2018","unstructured":"Rutherford AI, Patarata E, Subesinghe S, Hyrich KL, Galloway JB. Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British society for rheumatology biologics register for rheumatoid arthritis. Rheumatology (UK). 2018;57(6):997\u20131001. https:\/\/doi.org\/10.1093\/rheumatology\/key023.","journal-title":"Rheumatology (UK)"},{"issue":"3","key":"963_CR41","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jinf.2017.06.010","volume":"75","author":"C Schr\u00f6der","year":"2017","unstructured":"Schr\u00f6der C, Enders D, Schink T, Riedel O. Incidence of herpes zoster amongst adults varies by severity of immunosuppression. J Infect. 2017;75(3):207\u201315. https:\/\/doi.org\/10.1016\/j.jinf.2017.06.010.","journal-title":"J Infect"},{"issue":"8","key":"963_CR42","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/art.23112","volume":"57","author":"AL Smitten","year":"2007","unstructured":"Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 2007;57(8):1431\u20138. https:\/\/doi.org\/10.1002\/art.23112.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"963_CR43","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/ejh.13553","volume":"106","author":"V Steingr\u00edmsson","year":"2021","unstructured":"Steingr\u00edmsson V, G\u00edslason GK, \u00deorsteinsd\u00f3ttir S, et al. A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre-ibrutinib era. Eur J Haematol. 2021;106(3):346\u201353. https:\/\/doi.org\/10.1111\/ejh.13553.","journal-title":"Eur J Haematol"},{"issue":"7","key":"963_CR44","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/jama.2009.146","volume":"301","author":"A Strangfeld","year":"2009","unstructured":"Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301(7):737\u201344. https:\/\/doi.org\/10.1001\/jama.2009.146.","journal-title":"JAMA"},{"issue":"8","key":"963_CR45","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1016\/j.jid.2018.01.039","volume":"138","author":"J Takeshita","year":"2018","unstructured":"Takeshita J, Shin DB, Ogdie A, Gelfand JM. Risk of serious infection, opportunistic infection, and herpes zoster among patients with psoriasis in the United Kingdom. J Invest Dermatol. 2018;138(8):1726\u201335. https:\/\/doi.org\/10.1016\/j.jid.2018.01.039.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"963_CR46","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1093\/rheumatology\/keaa557","volume":"60","author":"K Thomas","year":"2021","unstructured":"Thomas K, Lazarini A, Kaltsonoudis E, et al. Incidence, risk factors and validation of the RABBIT score for serious infections in a cohort of 1557 patients with rheumatoid arthritis. Rheumatology (UK). 2021;60(5):2223\u201330. https:\/\/doi.org\/10.1093\/rheumatology\/keaa557.","journal-title":"Rheumatology (UK)"},{"issue":"12","key":"963_CR47","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.healun.2016.04.009","volume":"35","author":"NM van Besouw","year":"2016","unstructured":"van Besouw NM, van Hal PT, Zuijderwijk JM, et al. Herpes zoster after lung transplantation boosts varicella zoster virus-specific adaptive immune responses. J Heart Lung Transplant. 2016;35(12):1435\u201342. https:\/\/doi.org\/10.1016\/j.healun.2016.04.009.","journal-title":"J Heart Lung Transplant"},{"issue":"6","key":"963_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020528","volume":"8","author":"EA Yanni","year":"2018","unstructured":"Yanni EA, Ferreira G, Guennec M, et al. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the clinical practice research datalink 2000\u20132012. BMJ Open. 2018;8(6): e020528. https:\/\/doi.org\/10.1136\/bmjopen-2017-020528.","journal-title":"BMJ Open"},{"issue":"1","key":"963_CR49","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4321\/s1137-66272013000100006","volume":"36","author":"P Aldaz","year":"2013","unstructured":"Aldaz P, D\u00edaz JA, Loayssa JR, Dronda MJ, Osc\u00e1riz M, Castilla J. Herpes zoster incidence in diabetic patients. An Sist Sanit Navar. 2013;36(1):57\u201362. https:\/\/doi.org\/10.4321\/s1137-66272013000100006.","journal-title":"An Sist Sanit Navar"},{"issue":"1","key":"963_CR50","doi-asserted-by":"publisher","first-page":"66","DOI":"10.33393\/grhta.2020.2026","volume":"7","author":"S Calabria","year":"2020","unstructured":"Calabria S, Ronconi G, Dondi L, et al. Patterns of prescription, hospitalizations and costs of herpes zoster in patients at risk, from a large Italian claims database. Glob Reg Health Technol Assess. 2020;7(1):66\u201371. https:\/\/doi.org\/10.33393\/grhta.2020.2026.","journal-title":"Glob Reg Health Technol Assess"},{"issue":"9","key":"963_CR51","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.3899\/jrheum.131399","volume":"41","author":"R Baronaite Hansen","year":"2014","unstructured":"Baronaite Hansen R, Jacobsen S. Infections increase risk of arterial and venous thromboses in Danish patients with systemic lupus erythematosus: 5102 patient-years of follow up. J Rheumatol. 2014;41(9):1817\u201322. https:\/\/doi.org\/10.3899\/jrheum.131399.","journal-title":"J Rheumatol"},{"issue":"9","key":"963_CR52","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/apt.15689","volume":"51","author":"VB Biemans","year":"2020","unstructured":"Biemans VB, Sleutjes JA, De Vries AC, et al. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. Aliment Pharmacol Ther. 2020;51(9):880\u20138.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"963_CR53","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/bjd.17073","volume":"179","author":"R Blaizot","year":"2018","unstructured":"Blaizot R, Ouattara E, Fauconneau A, Beylot-Barry M, Pham-Ledard A. Infectious events and associated risk factors in mycosis fungoides\/S\u00e9zary syndrome: a retrospective cohort study. Br J Dermatol. 2018;179(6):1322\u20138. https:\/\/doi.org\/10.1111\/bjd.17073.","journal-title":"Br J Dermatol"},{"issue":"10","key":"963_CR54","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.bbmt.2014.06.002","volume":"20","author":"O Blennow","year":"2014","unstructured":"Blennow O, Fjaertoft G, Winiarski J, Ljungman P, Mattsson J, Remberger M. Varicella-zoster reactivation after allogeneic stem cell transplantation without routine prophylaxis\u2013the incidence remains high. Biol Blood Marrow Transplant. 2014;20(10):1646\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2014.06.002.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"963_CR55","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/ecco-jcc\/jjaa145","volume":"15","author":"M Chaparro","year":"2021","unstructured":"Chaparro M, Garre A, Mesonero F, et al. Tofacitinib in ulcerative colitis: real-world evidence from the ENEIDA registry. J Crohns Colitis. 2021;15(1):35\u201342.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"963_CR56","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00432-018-2807-1","volume":"145","author":"S Danhof","year":"2019","unstructured":"Danhof S, Strifler S, Hose D, et al. Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy. J Cancer Res Clin Oncol. 2019;145(3):561\u201371. https:\/\/doi.org\/10.1007\/s00432-018-2807-1.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"963_CR57","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaad.2020.03.033","volume":"83","author":"E Daud\u00e9n","year":"2020","unstructured":"Daud\u00e9n E, Carretero G, Rivera R, et al. Long-term safety of nine systemic medications for psoriasis: a cohort study using the Spanish registry of adverse events for biological therapy in dermatological diseases (BIOBADADERM) registry. J Am Acad Dermatol. 2020;83(1):139\u201350. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.033.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"963_CR58","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3390\/jpm11040249","volume":"11","author":"I Dogliotti","year":"2021","unstructured":"Dogliotti I, Ragaini S, Vassallo F, et al. Real life use of bendamustine in elderly patients with lymphoid neoplasia. J Pers Med. 2021;11(4):249. https:\/\/doi.org\/10.3390\/jpm11040249.","journal-title":"J Pers Med"},{"issue":"3","key":"963_CR59","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.autrev.2008.11.002","volume":"8","author":"EG Favalli","year":"2009","unstructured":"Favalli EG, Desiati F, Atzeni F, et al. Serious infections during anti-TNF\u03b1 treatment in rheumatoid arthritis patients. Autoimmun Rev. 2009;8(3):266\u201373. https:\/\/doi.org\/10.1016\/j.autrev.2008.11.002.","journal-title":"Autoimmun Rev"},{"issue":"6","key":"963_CR60","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1016\/j.transproceed.2005.06.067","volume":"37","author":"F Formicone","year":"2005","unstructured":"Formicone F, Fargnoli MC, Pisani F, Rascente M, Famulari A, Peris K. Cutaneous manifestations in Italian kidney transplant recipients. Transplant Proc. 2005;37(6):2527\u20138. https:\/\/doi.org\/10.1016\/j.transproceed.2005.06.067.","journal-title":"Transplant Proc"},{"issue":"4","key":"963_CR61","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10096-008-0628-x","volume":"28","author":"C Garcia-Vidal","year":"2009","unstructured":"Garcia-Vidal C, Rodr\u00edguez-Fern\u00e1ndez S, Teij\u00f3n S, et al. Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. Eur J Clin Microbiol Infect Dis. 2009;28(4):331\u20137. https:\/\/doi.org\/10.1007\/s10096-008-0628-x.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"963_CR62","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3816\/CLML.2010.n.019","volume":"10","author":"U Heider","year":"2010","unstructured":"Heider U, Rademacher J, Kaiser M, Kleeberg L, Von Metzler I, Sezer O. Decrease in CD4+ T-Cell counts in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma. 2010;10(2):134\u20137. https:\/\/doi.org\/10.3816\/CLML.2010.n.019.","journal-title":"Clin Lymphoma Myeloma"},{"issue":"6","key":"963_CR63","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/ane.13225","volume":"141","author":"J Hellgren","year":"2020","unstructured":"Hellgren J, Risedal A, K\u00e4ll\u00e9n K. Rituximab in multiple sclerosis at general hospital level. Acta Neurol Scand. 2020;141(6):491\u20139. https:\/\/doi.org\/10.1111\/ane.13225.","journal-title":"Acta Neurol Scand"},{"issue":"9","key":"963_CR64","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1002\/lt.20219","volume":"10","author":"JI Herrero","year":"2004","unstructured":"Herrero JI, Quiroga J, Sangro B, et al. Herpes zoster after liver transplantation: incidence, risk factors, and complications. Liver Transpl. 2004;10(9):1140\u20133. https:\/\/doi.org\/10.1002\/lt.20219.","journal-title":"Liver Transpl"},{"issue":"10","key":"963_CR65","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/ecco-jcc\/jjaa075","volume":"14","author":"S Honap","year":"2020","unstructured":"Honap S, Chee D, Chapman TP, et al. Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience. J Crohns Colitis. 2020;14(10):1385\u201393.","journal-title":"J Crohns Colitis"},{"key":"963_CR66","doi-asserted-by":"publisher","first-page":"9","DOI":"10.12659\/aot.883792","volume":"18","author":"J Kaden","year":"2013","unstructured":"Kaden J, V\u00f6lp A, Wesslau C. High graft protection and low incidences of infections, malignancies and other adverse effects with intra-operative high dose ATG-induction: a single centre cohort study of 760 cases. Ann Transplant. 2013;18:9\u201322. https:\/\/doi.org\/10.12659\/aot.883792.","journal-title":"Ann Transplant"},{"issue":"4","key":"963_CR67","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/bmt.2014.290","volume":"50","author":"C Kamber","year":"2015","unstructured":"Kamber C, Zimmerli S, Suter-Riniker F, et al. Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients. Bone Marrow Transplant. 2015;50(4):573\u20138. https:\/\/doi.org\/10.1038\/bmt.2014.290.","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"963_CR68","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.dld.2018.07.007","volume":"50","author":"MV Lenti","year":"2018","unstructured":"Lenti MV, Levison S, Eliadou E, et al. A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: the cross Pennine study. Dig Liver Dis. 2018;50(12):1299\u2013304. https:\/\/doi.org\/10.1016\/j.dld.2018.07.007.","journal-title":"Dig Liver Dis"},{"key":"963_CR69","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X19878004","author":"L Leon","year":"2019","unstructured":"Leon L, Pe\u00f1uelas M, Candel FJ, et al. Indicator opportunistic infections after biological treatment in rheumatoid arthritis, 10 years follow-up in a real-world setting. Ther Adv Musculoskelet Dis. 2019. https:\/\/doi.org\/10.1177\/1759720X19878004.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"963_CR70","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/sj.leu.2402784","volume":"17","author":"F Maloisel","year":"2003","unstructured":"Maloisel F, Benboubker L, Gardembas M, et al. Long-term outcome with pentostatin treatment in hairy cell leukemia patients: a French retrospective study of 238 patients. Leukemia. 2003;17(1):45\u201351. https:\/\/doi.org\/10.1038\/sj.leu.2402784.","journal-title":"Leukemia"},{"issue":"3\u20134","key":"963_CR71","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1159\/000106065","volume":"71","author":"G Masci","year":"2006","unstructured":"Masci G, Magagnoli M, Gullo G, et al. Herpes infections in breast cancer patients treated with adjuvant chemotherapy. Oncology. 2006;71(3\u20134):164\u20137. https:\/\/doi.org\/10.1159\/000106065.","journal-title":"Oncology"},{"issue":"8","key":"963_CR72","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1007\/s10067-021-05646-2","volume":"40","author":"B Obri\u0219c\u0103","year":"2021","unstructured":"Obri\u0219c\u0103 B, Vornicu A, Jurubi\u021b\u0103 R, et al. Corticosteroids are the major contributors to the risk for serious infections in autoimmune disorders with severe renal involvement. Clin Rheumatol. 2021;40(8):3285\u201397. https:\/\/doi.org\/10.1007\/s10067-021-05646-2.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"963_CR73","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3816\/CLM.2009.n.036","volume":"9","author":"L Pour","year":"2009","unstructured":"Pour L, Adam Z, Buresova L, et al. Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma. 2009;9(2):151\u20133. https:\/\/doi.org\/10.3816\/CLM.2009.n.036.","journal-title":"Clin Lymphoma Myeloma"},{"issue":"4","key":"963_CR74","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/ejh.13588","volume":"106","author":"A Rampotas","year":"2021","unstructured":"Rampotas A, Djebbari F, Panitsas F, et al. Efficacy and tolerability of VCD chemotherapy in a UK real-world dataset of elderly transplant-ineligible newly diagnosed myeloma patients. Eur J Haematol. 2021;106(4):563\u201373. https:\/\/doi.org\/10.1111\/ejh.13588.","journal-title":"Eur J Haematol"},{"issue":"8","key":"963_CR75","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/j.transproceed.2006.08.060","volume":"38","author":"A Rodriguez-Moreno","year":"2006","unstructured":"Rodriguez-Moreno A, Sanchez-Fructuoso AI, Calvo N, et al. Varicella infection in adult renal allograft recipients: experience at one center. Transplant Proc. 2006;38(8):2416\u20138. https:\/\/doi.org\/10.1016\/j.transproceed.2006.08.060.","journal-title":"Transplant Proc"},{"issue":"12","key":"963_CR76","doi-asserted-by":"publisher","first-page":"686","DOI":"10.20452\/pamw.2013","volume":"123","author":"J Sulowicz","year":"2013","unstructured":"Sulowicz J, Wojas-Pelc A, Kuzniewski M, Ignacak E, Janda K, Sulowicz W. Cutaneous viral infections in patients after kidney transplantation: risk factors. Polskie Arch Med Wewnetrznej. 2013;123(12):686\u201392. https:\/\/doi.org\/10.20452\/pamw.2013.","journal-title":"Polskie Arch Med Wewnetrznej."},{"issue":"11","key":"963_CR77","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/sj.bmt.1704959","volume":"35","author":"KJ Thomson","year":"2005","unstructured":"Thomson KJ, Hart DP, Banerjee L, Ward KN, Peggs KS, Mackinnon S. The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant. 2005;35(11):1065\u20139. https:\/\/doi.org\/10.1038\/sj.bmt.1704959.","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"963_CR78","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s00277-015-2423-y","volume":"94","author":"J Tischer","year":"2015","unstructured":"Tischer J, Engel N, Fritsch S, et al. Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings. Ann Hematol. 2015;94(10):1677\u201388. https:\/\/doi.org\/10.1007\/s00277-015-2423-y.","journal-title":"Ann Hematol"},{"issue":"6","key":"963_CR79","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s00277-004-0858-7","volume":"83","author":"E Van Den Neste","year":"2004","unstructured":"Van Den Neste E, Michaux L, Layios N, et al. High incidence of complications after 2-chloro-2\u2019-deoxyadenosine combined with cyclophosphamide in patients with advanced lymphoproliferative malignancies. Ann Hematol. 2004;83(6):356\u201363. https:\/\/doi.org\/10.1007\/s00277-004-0858-7.","journal-title":"Ann Hematol"},{"issue":"10","key":"963_CR80","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.dld.2014.07.006","volume":"46","author":"M van der Have","year":"2014","unstructured":"van der Have M, Belderbos TDG, Fidder HH, et al. Screening prior to biological therapy in Crohn\u2019s disease: Adherence to guidelines and prevalence of infections\u2014results from a multicentre retrospective study. Dig Liver Dis. 2014;46(10):881\u20136. https:\/\/doi.org\/10.1016\/j.dld.2014.07.006.","journal-title":"Dig Liver Dis"},{"issue":"11","key":"963_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ofid\/ofz445","volume":"6","author":"E Zappulo","year":"2019","unstructured":"Zappulo E, Buonomo AR, Sacc\u00e0 F, et al. Incidence and predictive risk factors of infective events in patients with multiple sclerosis treated with agents targeting CD20 and CD52 surface antigens. Open Forum Infect Dis. 2019;6(11):1\u20139. https:\/\/doi.org\/10.1093\/ofid\/ofz445.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"963_CR82","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/1471-2334-14-364","volume":"14","author":"JC Nissen","year":"2014","unstructured":"Nissen JC, Hummel M, Brade J, et al. The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage: a single center experience. BMC Infect Dis. 2014;14(1):364. https:\/\/doi.org\/10.1186\/1471-2334-14-364.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"963_CR83","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.dld.2019.10.003","volume":"52","author":"L Lair-Mehiri","year":"2020","unstructured":"Lair-Mehiri L, Stefanescu C, Vaysse T, et al. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Dig Liver Dis. 2020;52(3):268\u201373.","journal-title":"Dig Liver Dis"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-00963-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-024-00963-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-00963-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T05:16:17Z","timestamp":1715836577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-024-00963-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":83,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["963"],"URL":"https:\/\/doi.org\/10.1007\/s40121-024-00963-w","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,24]]},"assertion":[{"value":"4 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Amit Bhavsar, Alen Marijam, Inga Posiuniene and Nicolas Lecrenier are employed by and hold shares in GSK. Hilde Vroling and Nikki Vroom are employees of P95\/Pallas. P95\/Pallas received funding from GSK for the submitted work. P95\/Pallas holds\/held contracts with AstraZeneca, GSK, Pfizer, Sanofi and Seqirus, Orchard, BioMarin, Daiichi, Bavarian Nordic and Bayer. The authors declare no other financial and non-financial relationships and activities and no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Shingrix is a trademark owned by or licensed to GSK. Zostavax is a trademark of MSD.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Trademark Statement"}}]}}